OKLAHOMA CITY - The Wyeth Pharmaceuticals Inc. subsidiary of Pfizer Inc. has pleaded guilty to misbranding and paid $490.9 million in criminal and civil penalties to resolve allegations that it marketed its Rapamune anti-rejection drug for off-label uses, the U.S. Justice Department announced July 30 (United States of America v. Wyeth Pharmaceuticals Inc., et al., No. 5:13-cr-129, United States of America, ex rel. Mark B. Campbell v. Wyeth Inc., No. 5:07-cv-51, W.D. Okla., and United States of America ex rel. Marlene Sandler, et al. v. Wyeth Pharmaceuticals, Inc., No. 5:10-cv-1317, E.D. Pa.).